Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 7, 2007, Pages 1064-1070

  Woo, Mijung ^b   Park, Kyungsook ^b   Nam, Junghyun ^b   Kim, Jin C ^a,c  

^a University of Ulsan College of Medicine   (South Korea)

^b Sungshin Women's University   (South Korea)

^c Asan Institute for Life Sciences   (South Korea)

Author keywords

Colorectal cancer; Matrix metalloproteinase; Plasminogen activator inhibitor; Polymorphism

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; STROMELYSIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER PATIENT; CANCER SUSCEPTIBILITY; CHROMOSOME 20Q; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 34347372303     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04424.x     Document Type: Article

References (35)

1. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002 2 : 161 74.
2. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004 23 : 101 17.
3. Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev. 2004 23 : 119 35.
4. Inuzuka K, Ogata Y, Nagase H, Shirouzu K. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J. Surg. Res. 2000 93 : 211 18.
5. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J. Surg. 2002 26 : 767 71.
6. Roeb E, Dietrich CG, Winograd R et al. Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9. Cancer 2001 92 : 2680 91.
7. Rutter JL, Mitchell TI, Buttice G et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998 58 : 5321 5.
8. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J. Biol. Chem. 1996 271 : 13055 60.
9. Jormsjo S, Whatling C, Walter DH, Zeiher AM, Hamsten A, Eriksson P. Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 2001 21 : 1834 9.
10. Zhang B, Ye S, Herrmann SM et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999 99 : 1788 94.
11. Shimajiri S, Arima N, Tanimoto A et al. Shortened microsatellite d (CA) 21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett. 1999 455 : 70 4.
12. Morgan AR, Zhang B, Tapper W, Collins A, Ye S. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J. Mol. Med. 2003 81 : 321 6.
13. Jormsjo S, Ye S, Moritz J et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ. Res. 2000 86 : 998 1003.
14. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. USA 1995 92 : 1851 5.
15. Houlston RS, Tomlinson IP. Polymorphisms and colorectal tumor risk. Gastroenterology 2001 121 : 282 301.
16. Hinoda Y, Okayama N, Takano N et al. Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP3 genes with colorectal cancer. Int. J. Cancer 2002 102 : 526 9.
17. Fang S, Jin W, Wang R et al. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 2004 26 : 481 6.
18. Matsumura S, Oue N, Nakayama H et al. A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J. Cancer Res. Clin. Oncol. 2005 131 : 19 25.
19. Maeda S, Haneda M, Guo B et al. Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. Kidney Int. 2001 60 : 1428 34.
20. Hirakawa S, Lange EM, Colicigno CJ, Freedman BI, Rich SS, Bowden DW. Evaluation of genetic variation and association in the matrix metalloproteinase 9 (MMP9) gene in ESRD patients. Am. J. Kidney Dis. 2003 42 : 133 42.
21. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat. Med. 2004 23 : 1663 82.
22. Ghilardi G, Biondi ML, Mangoni J et al. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin. Cancer Res. 2001 7 : 2344 6.
23. Ghilardi G, Biondi ML, Caputo M et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin. Cancer Res. 2002 8 : 3820 3.
24. Matsumura S, Oue N, Kitadai Y et al. A single nucleotide polymorphism in the MMP1 promoter is correlated with histological differentiation of gastric cancer. J. Cancer Res. Clin. Oncol. 2004 130 : 259 65.
25. Holla LI, Jurajda M, Fassmann A, Dvorakova N, Znojil V, Vacha J. Genetic variations in the matrix metalloproteinase-1 promoter and risk of susceptibility and/or severity of chronic periodontitis in the Czech population. J. Clin. Periodontol. 2004 31 : 685 90.
26. Przybylowska K, Zielinska J, Zadrozny M et al. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer. J. Exp. Clin. Cancer Res. 2004 23 : 121 5.
27. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001 61 : 7825 9.
28. Kim JC, Lee KH, Ka IH et al. Characterization of mutator phenotype in familial colorectal cancer patients not fulfilling Amsterdam criteria. Clin. Cancer Res. 2004 15 : 6159 68.
29. Zinzindohoue F, Lecomte T, Ferraz JM et al. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin. Cancer Res. 2005 11 : 594 9.
30. Krippl P, Langsenlehner U, Renner W et al. The 5A/6A polymorphism of the matrix metalloproteinase 3 gene promoter and breast cancer. Clin. Cancer Res. 2004 10 : 3518 20.
31. Ghilardi G, Biondi ML, Erario M, Guagnellini E, Scorza R. Colorectal carcinoma susceptibility and metastases are associated with matrix metalloproteinase-7 promoter polymorphisms. Clin. Chem. 2003 49 : 1940 2.
32. Wang Y, Fang S, Wei L et al. No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer 2005 49 : 155 61.
33. Joos L, He JQ, Shepherdson MB et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum. Mol. Genet. 2002 11 : 569 76.
34. Nielsen HJ, Pappot H, Christensen IJ et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ 1998 316 : 829 30.
35. Loktionov A, Watson MA, Stebbings WS, Speakman CT, Bingham SA. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Lett. 2003 189 : 189 96.